Eating disorders are on the rise. GLP-1s could make things worse.
GLP-1 weight-loss drugs are one of the biggest biotech breakthroughs of the last decade. But to some clinical psychologists, they can represent something more sinister—a potential trigger for eating disorders. A new report suggests that the global incidence of anorexia nervosa and bulimia nervosa shot up between 1990 and 2023—by a whopping 71%. By 2023,…
Se muestra el contenido original; la traduccion localizada aun no esta disponible.
Qué ocurrió
GLP-1 weight-loss drugs are one of the biggest biotech breakthroughs of the last decade. But to some clinical psychologists, they can represent something more sinister—a potential trigger for eating disorders. A new report suggests that the global incidence of anorexia nervosa and bulimia nervosa shot up between 1990 and 2023—by a whopping 71%. By 2023,…
Por que importa
The development may change operating conditions or market expectations around AI. Further confirmation and measurable outcomes matter.
Entidades afectadas
Ver evidencia
1 articulos · 1 informe original · 1 independientes
- MIT Technology ReviewFuente primaria · Respalda · EN · 100%Eating disorders are on the rise. GLP-1s could make things worse. ↗
Afirmaciones
- Eating disorders are on the rise. GLP-1s could make things worse. Reportado
Conflictos
No se detectaron conflictos importantes en la evidencia disponible.
Cronología
- Primera publicación
Movimiento del mercado posterior al evento
La reacción del mercado aún no está disponible para este activo y periodo.